Significantly, NSCLC, enriched for EGFR gene mutation (EGFR-activating mutations in exons 1821), has demonstrated enhanced sensitivity to EGFR tyrosine kinase inhibitors (TKIs, gefitinib) [111,112]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.